The rise of single-use technologies (SUT) in pharma has shown no signs of abating and is continuing to transform every area of operations. “The global single-use bioprocessing market was valued at $12.6 billion in 2019 and is projected to witness a CAGR of 12.8 percent by 2027,” says Mark A. Sitcoske, CEO of High Purity New England. “SUT continues to experience huge growth in 2020 in pre-commercial manufacturing, including preclinical and clinical scale systems for upstream processing, such as single-use media bags, bioprocess containers and mixers.” In addition to preclinical applications, pharma is turning to… Click Here For Complete Article Text
|
||||||||||||||||||
Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|